Saad Mark E 4

What Happened
Mark E. Saad, a director of Axsome Therapeutics, reported the conversion/exercise of 1,429 restricted stock units (RSUs) into 1,429 shares of common stock on June 8, 2026. The Form 4 shows an "acquired" entry for 1,429 shares (price N/A) and a corresponding "disposed" entry for 1,429 shares at $0.00 (derivative). Footnotes state the RSUs were granted on June 6, 2025 and vested on their one-year anniversary; RSUs convert into common stock on a one-for-one basis.

Key Details

• Transaction date: 2026-06-08; Form 4 filed 2026-06-10 (timely filing).
• Shares converted: 1,429 RSUs → 1,429 common shares. Reported disposal: 1,429 shares at $0.00.
• Price/Value: Acquisition line shows N/A; disposal line shows $0.00 (no cash sale proceeds reported).
• Ownership note: Footnote indicates additional shares were held indirectly by Mr. Saad prior to June 10, 2026, including shares held as custodian for his children's UTMA accounts.
• Filing details: No 10b5-1 plan, late filing indicator, or dollar proceeds are reported in the provided entries.

Context
This was a conversion/vesting event (RSUs converting into common stock), not an open-market purchase or sale. The filing lists both an acquisition and a $0.00 disposition for the same number of shares; the form does not specify the reason for the $0.00 disposition in its entries. Retail investors should view this as a routine equity award vesting/conversion disclosure rather than a market sale or buy signal.